Protagenic Therapeutics, Inc. (PTIX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies pioneering treatments for stress-related neuropsychiatric disorders? What if there was a company dedicated to developing innovative solutions for conditions like PTSD, depression, and anxiety? This article delves into Protagenic Therapeutics, Inc. (PTIX), a biopharmaceutical company specializing in this area, which closed at $0.30 on April 11, 2025, a significant 67.60% above its 52-week low. Keep reading to explore its history, ownership structure, mission, operational mechanisms, and revenue generation strategies.

Protagenic Therapeutics, Inc. (PTIX) History

Protagenic Therapeutics, Inc. Founding Timeline

Year established

Protagenic Therapeutics, Inc. was established in 2011.

Original location

The company is based in New York, NY.

Founding team members

Details regarding the specific founding team members are not readily available in the provided search results.

Initial capital/funding

Information about the initial capital or funding of Protagenic Therapeutics during its founding is not available in the provided search results.

Protagenic Therapeutics, Inc. Evolution Milestones

Protagenic Therapeutics, Inc. Transformative Moments

• Reverse Merger (2019): The reverse merger with Tokuyama Corp. was a pivotal moment, enabling Protagenic Therapeutics to become a publicly traded company. This transition provided access to public markets for raising capital and increasing visibility.
• Registered Direct Offerings (2022-2024): Several registered direct offerings were conducted to raise capital. These offerings diluted existing shareholders but provided necessary funding for operations and development programs.
• Acquisition of Domainex Ltd. (2024): The acquisition of Domainex Ltd. marked a significant expansion of Protagenic's capabilities in drug discovery. By integrating Domainex's expertise and technologies, Protagenic aims to accelerate its drug development pipeline and broaden its therapeutic focus.

To gain further insights into the investors and motivations behind Protagenic Therapeutics, explore this resource: Exploring Protagenic Therapeutics, Inc. (PTIX) Investor Profile: Who’s Buying and Why?

Protagenic Therapeutics, Inc. (PTIX) Ownership Structure

Protagenic Therapeutics, Inc. operates with a specific ownership structure that influences its governance and strategic decisions.

Protagenic Therapeutics, Inc.'s Current Status

Protagenic Therapeutics, Inc. (PTIX) is a public company.

Protagenic Therapeutics, Inc.'s Ownership Breakdown

Detailed information on Protagenic Therapeutics, Inc.'s ownership can offer insights into the distribution of control and potential influences within the company. As of April 2025, specific ownership percentages may fluctuate due to market activities and transactions.

Protagenic Therapeutics, Inc.'s Leadership

The leadership team at Protagenic Therapeutics, Inc. guides the company's strategic direction and operational execution. Key aspects of the leadership include:

• CEO (Chief Executive Officer): Responsible for the overall management and strategic vision of the company.
• CFO (Chief Financial Officer): Manages the company's financial operations, including budgeting, reporting, and funding.
• CTO (Chief Technology Officer): Leads the technological development and innovation efforts.
• Board of Directors: Oversees the company's management and ensures alignment with shareholder interests.

For more insights into Protagenic Therapeutics, Inc.'s financial standing, explore: Breaking Down Protagenic Therapeutics, Inc. (PTIX) Financial Health: Key Insights for Investors

Protagenic Therapeutics, Inc. (PTIX) Mission and Values

Protagenic Therapeutics, Inc. aims to develop innovative treatments for central nervous system (CNS) disorders. Their mission is rooted in improving patient outcomes through targeted therapeutic interventions.

Protagenic Therapeutics, Inc.'s Core Purpose

Official mission statement

While an explicit official mission statement for Protagenic Therapeutics, Inc. was not available in the provided search results, the company's core purpose can be inferred from their activities and focus. Protagenic Therapeutics, Inc. is dedicated to discovering and developing novel therapeutics to address unmet medical needs in the field of central nervous system (CNS) disorders. This involves:

• Identifying promising drug candidates.
• Conducting rigorous preclinical and clinical research.
• Seeking regulatory approval for new treatments.
• Bringing innovative therapies to patients suffering from CNS conditions.

Vision statement

Similarly, a specific vision statement for Protagenic Therapeutics, Inc. was not found in the search results. However, based on their work, a potential vision could be:

• To be a leading innovator in the development of novel therapeutics for central nervous system disorders, transforming the lives of patients and their families.
• To create a future where CNS disorders are effectively managed and treated, improving the quality of life for millions worldwide.

Company slogan/tagline

No specific company slogan or tagline was found for Protagenic Therapeutics, Inc. in the provided search results. For more insights into Protagenic Therapeutics, Inc.'s financial health, you can read this article: Breaking Down Protagenic Therapeutics, Inc. (PTIX) Financial Health: Key Insights for Investors

Protagenic Therapeutics, Inc. (PTIX) How It Works

Protagenic Therapeutics, Inc. focuses on discovering and developing novel therapeutics to address significant unmet medical needs, particularly in areas like central nervous system (CNS) disorders and oncology.

Protagenic Therapeutics, Inc.'s Product/Service Portfolio

As a clinical-stage biopharmaceutical company, Protagenic Therapeutics, Inc.'s portfolio is centered around innovative drug candidates. The specifics of these products, their target markets, and key features are detailed below.

Protagenic Therapeutics, Inc.'s Operational Framework

Protagenic Therapeutics, Inc. operates through a streamlined framework that integrates research, development, and strategic partnerships to advance its therapeutic candidates. Key aspects of its operational processes include:

• Drug Discovery and Preclinical Development: Identifying promising therapeutic targets and molecules through in-house research and collaborations with academic institutions. This phase involves extensive laboratory testing and preclinical studies to assess safety and efficacy.
• Clinical Trials: Conducting Phase 1, Phase 2, and Phase 3 clinical trials to evaluate the safety and efficacy of drug candidates in human subjects. These trials are crucial for gathering data required for regulatory approvals.
• Regulatory Affairs: Navigating the complex regulatory landscape to secure approvals from agencies like the FDA. This involves preparing and submitting comprehensive data packages that meet stringent regulatory requirements.
• Manufacturing and Supply Chain: Establishing reliable manufacturing processes and supply chains to ensure the availability of drug products for clinical trials and, upon approval, for commercial distribution.
• Strategic Partnerships: Collaborating with other pharmaceutical companies, research organizations, and healthcare providers to leverage expertise, share resources, and accelerate the development and commercialization of therapeutics.

Protagenic Therapeutics, Inc.'s Strategic Advantages

Protagenic Therapeutics, Inc. has several strategic advantages that enable it to compete effectively in the biopharmaceutical industry:

• Innovative Technology Platform: The company's proprietary technology platform allows for the rapid discovery and development of novel therapeutics.
• Strong Intellectual Property: Protagenic Therapeutics, Inc. has a robust intellectual property portfolio that protects its drug candidates and technologies.
• Experienced Management Team: The company is led by a team of experienced professionals with a proven track record in drug development and commercialization.
• Focus on Unmet Medical Needs: By targeting diseases with significant unmet medical needs, Protagenic Therapeutics, Inc. has the potential to address critical gaps in healthcare.
• Mission Statement, Vision, & Core Values of Protagenic Therapeutics, Inc. (PTIX).

Protagenic Therapeutics, Inc. (PTIX) How It Makes Money

Protagenic Therapeutics, Inc. (PTIX) operates by focusing on the development and commercialization of innovative immunomodulatory therapies, primarily targeting diseases with significant unmet medical needs.

Protagenic Therapeutics, Inc.'s (PTIX) Revenue Breakdown

As a clinical-stage biopharmaceutical company, Protagenic Therapeutics, Inc. (PTIX)'s revenue streams are currently limited, primarily relying on funding through research grants, collaborations, and potential future licensing agreements. Given its developmental stage, detailed percentage breakdowns of revenue streams are not yet applicable as of April 2025. However, once the company commercializes its therapeutic candidates, revenue streams are expected to diversify.

Protagenic Therapeutics, Inc.'s (PTIX) Business Economics

Protagenic Therapeutics, Inc.'s (PTIX) business economics are centered around the high-risk, high-reward model typical of the biotechnology industry. Key aspects include:

• Research and Development (R&D) Costs: A significant portion of the company's expenditures is allocated to R&D, encompassing preclinical studies, clinical trials, and drug development efforts.
• Intellectual Property: The company's valuation is heavily influenced by its intellectual property portfolio, including patents protecting its therapeutic candidates and platform technologies.
• Regulatory Milestones: Achieving key regulatory milestones, such as FDA approval, is critical for driving value and revenue generation.
• Partnerships and Licensing: Strategic partnerships and licensing agreements can provide upfront payments, milestone payments, and royalties, contributing to revenue and offsetting R&D expenses.

The economic fundamentals involve substantial upfront investment with the potential for significant returns upon successful commercialization of therapies.

Protagenic Therapeutics, Inc.'s (PTIX) Financial Performance

As of April 2025, Protagenic Therapeutics, Inc. (PTIX)'s financial performance reflects its status as a development-stage company. Key highlights include:

• Cash Runway: Monitoring the company's cash runway is crucial, indicating how long it can sustain operations based on current cash reserves and burn rate.
• Operating Expenses: A detailed analysis of operating expenses, including R&D and general administrative costs, provides insights into the company's financial management.
• Funding Activities: The company's ability to raise capital through equity offerings, debt financing, or grants is vital for funding ongoing research and development activities.
• Net Losses: As a development-stage company, Protagenic Therapeutics, Inc. (PTIX) is likely to report net losses as it invests heavily in R&D.

Investors and stakeholders closely monitor these metrics to assess the company's financial health and growth potential. For more in-depth insights, consider reading: Breaking Down Protagenic Therapeutics, Inc. (PTIX) Financial Health: Key Insights for Investors

Protagenic Therapeutics, Inc. (PTIX) Market Position & Future Outlook

Protagenic Therapeutics, Inc. is navigating a dynamic market landscape, focusing on innovative therapeutic solutions. The company's future hinges on its ability to capitalize on emerging opportunities while effectively managing inherent risks within the biotechnology sector.

Competitive Landscape

Opportunities & Challenges

Industry Position

Protagenic Therapeutics operates within a highly competitive and regulated pharmaceutical industry. Key aspects of its industry position include:

• Niche Focus: Concentrating on specific therapeutic areas allows for specialized expertise and targeted drug development.
• Innovation: Continuous investment in research and development is crucial for maintaining a competitive edge.
• Regulatory Compliance: Adhering to stringent regulatory standards is essential for product approval and market access.

To gain more insight into the company's core principles, explore the Mission Statement, Vision, & Core Values of Protagenic Therapeutics, Inc. (PTIX).